PCM
HRMY icon

Polymer Capital Management’s Harmony Biosciences HRMY Stock Holding History

Polymer Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,697
Closed -$213K – 909
2025
Q4 		$213K Buy
+5,697
New +$187K 0.02% 690
2025
Q2 		– Sell
-6,602
Closed -$219K – 679
2025
Q1 		$219K Buy
+6,602
New +$237K 0.06% 426

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Polymer Capital Management's HRMY Position: Q1 2026 in Review

Polymer Capital Management sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 5,697 shares — an estimated $213K sold.

Polymer Capital Management first reported a position in HRMY in Q1 2025 and held it in 2 quarters. The position peaked at $219K in Q1 2025. 311 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Polymer Capital Management reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
  • Polymer Capital Management sold 5,697 Harmony Biosciences shares in Q1 2026, an estimated $213K.
  • Polymer Capital Management first reported a position in Harmony Biosciences in Q1 2025 and held it in 2 quarters.
  • Polymer Capital Management's Harmony Biosciences position peaked at $219K in Q1 2025.
  • 311 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Polymer Capital Management's 13F filing for Q1 2026, filed 14 May 2026.